Antipsychotic Use Among Youth Ups Type 2 Diabetes Risk
Elevated risk seen during first year of use; risk increases with increasing cumulative dose
THURSDAY, Aug. 22 (HealthDay News) -- Among youth aged 6 to 24 years, recent initiation of antipsychotics is associated with a significantly increased risk of type 2 diabetes, according to a study published online Aug. 21 in JAMA Psychiatry.
William V. Bobo, M.D., M.P.H., from the Vanderbilt University School of Medicine in Nashville, Tenn., and colleagues compared the risk of type 2 diabetes in children and youth aged 6 to 24 years in a cohort of 28,858 recent initiators of antipsychotic drugs and 14,429 matched controls.
The researchers found that the risk of type 2 diabetes was significantly increased for users of antipsychotics (hazard ratio [HR], 3.03), which was seen within the first year of follow-up (HR, 2.49). During follow-up, the risk increased with cumulative dose (HRs: 2.13 for up to 5 g, 3.42 for 5 to 99 g, and 5.43 for 100 g or more). For up to one year following discontinuation of antipsychotics, the risk remained elevated (HR, 2.57). The risk of type 2 diabetes was increased more than three-fold on restriction of the cohort to children aged 6 to 17 years (HR, 3.14), with significantly increased risk seen with increasing cumulative dose. On restriction of the analyses to atypical antipsychotics or to risperidone, the risk was significantly increased (HR, 2.89 and 2.20, respectively).
"Risk was elevated during the first year of antipsychotic use, increased with increasing cumulative dose, and was present for children younger than 18 years of age," the authors write.
Two authors disclosed financial ties to the pharmaceutical industry.
Abstract (http://archpsyc.jamanetwork.com/article.aspx?articleid=1731662#Abstract )Full Text (subscription or payment may be required) (http://archpsyc.jamanetwork.com/article.aspx?articleid=1731662 )